SUMMARY Wheat gluten derived antigens have been tested for their ability to inhibit the migration of leucocytes from healthy subjects and patients with coeliac disease. Three preparations of a water soluble fraction (Frazer's fraction III, FIII) of partial peptic tryptic digests of wheat gluten had different effects in a direct (one stage) assay. Subfractions B and B2 caused migration inhibition of leucocytes from patients with treated coeliac disease but not of leucocytes from healthy volunteers or patients with Crohn's disease or ulcerative colitis. This migration inhibition seems to be specific for gluten fractions because maize zein fraction B, ,3-lactoglobulin and ovalbumin did not cause it. The sensitivity of coeliac leucocytes to fraction B is not related to factors present in coeliac serum as the migration of leucocytes from healthy individuals preincubated with coeliac sera was not inhibited. Puromycin diminished inhibition by fraction B, which was active at 1.2 [ig/ml in an indirect (two stage) migration inhibition assay; this is consistent with a process involving elaboration of lymphokine(s). More highly purified fractions of B2, P1-P4 were prepared by reverse phase high performance liquid chromatography (HPLC) and showed differing potency in direct and indirect assays, with P4 being the most active fraction. Inhibition of migration by gluten derived peptides appears to result from the release of lymphokine by leucocytes specifically from coeliac patients.
Since Dicke' first established the toxicity of wheat gluten in patients with coeliac disease there have been numerous attempts to identify its toxic component. Frazer et al2 showed that a water soluble fraction (fraction III, FIII) of a partial peptic tryptic digest of gluten retained its damaging properties. Dissanayake et all separated FIII into three fractions (A, B, and C) by ultrafiltration. By feeding studies, in volunteer patients with treated coeliac disease, they showed that fraction A (lowest molecular weight) was not harmful, but that fractions B and C produced histological damage. Anand More recently, fraction B2 has been further separated using reverse-phase HPLC. The peaks fell into four main groups, designated P1 to P4, each containing several peptides.'2 Results using these peptide fractions in both the direct and the indirect leucocyte migration inhibition assay are described.
Methods

PATIENTS
Twenty two patients with coeliac disease were studied. All had villous atrophy consistent with coeliac disease at the time of presentation, and all had a good clinical and histological response to a gluten free diet and remained well on the diet at the time of testing.
Two groups of similar age and sex distribution were chosen as controls; 13 hospital staff and 10 patients with quiescent inflammatory bowel disease (one with chronic colitis of undetermined type; four with ulcerative colitis; and five with Crohn's diseaseof whom two had colitis, one had terminal ileal disease, and two had both ileal and colonic disease). No patient was being treated with corticosteroids or immunosuppressives.
GLUTEN FRACTIONS
Fraction III from a peptic tryptic digest of gluten was prepared by the method of Frazer et Frazer's fraction III prepared in Oxford from Flanders wheat as well as from Scout 66 wheat had no effect on the migration of leucocytes from either healthy individuals or patients with coeliac disease at concentrations as high as 1 mg/ml (Flanders fraction III: healthy controls (n=7), mean migration index= 1-12; coeliacs (n=14), mean migration index=1-08; no significant difference, p>0-1; Scout 66 fraction III: healthy controls (n=7), mean migration index= 1-10; coeliacs (n=7), mean migration index= 1-08; no significant difference, p>0.5) (Fig. 1) . Fl-anders fraction III, however, showed a lower migration index after inactivation of trypsin with both normal (p<0.02) and coeliac (p<0-05) leucocytes.
Fraction III from Leeds inhibited leucocyte migration in patients with coeliac disease at 1 mg/ml (compared with healthy controls, p<0-001). Significant inhibition was seen even at 10 [ig/ml (compared with healthy controls, p<0.001). This antigen also inhibited the migration of leucocytes from patients in the disease control group at 1 mg/ml (Fig. 1) .
Alpha/beta/gamma gliadins (100 ,ug/ml and 1 mg/ml) failed to inhibit the migration of leucocytes from either coeliac patients or normal individuals (100 [ig/ml: healthy controls (n=7), mean migration index=0-96; coeliacs (n=6), mean migration index= 0.98. 1 mg/ml: healthy controls (n=7), mean migration index=0-99; coeliacs (n=6), mean migration index=0.92). 'Late-eluting' gliadins, however, tended to inhibit migration of leucocytes from coeliac patients at 100 ,ug/ml, although this did not reach statistical significance at the 5% level (10 ptg/ml: healthy controls (n=11), mean migration index= 1-07; coeliacs (n=9), mean migration index=1-01; p>0-1. 100 ,ug/ml: healthy controls (n=11), mean migration index=1.00; coeliacs (n= 11), mean migration index=0-89; 0.1>p>0.05).
Fractions B and B2 of Scout 66 wheat had no effect on the migration of leucocytes from healthy subjects (Fig. 2) . For fraction B the largest difference between patients and healthy controls was at 10 pg/ml (p<0-0-1). For subfraction B2 the difference was greatest at 100 ,ug/ml (p<0-001) (Fig. 3) . The migra- tion index for normal controls fell below 1-0 at the highest dose of 1 mg/ml when a reduction in cell viability was seen after the preincubation period. The migration of leucocytes from patients with coeliac disease was not significantly inhibited by zein fraction B (100 .tg/ml: healthy controls (n=8), mean migration index= 1-09; coeliacs (n= 12), mean migration index= 1.05), nor by f-lactoglobulin (100 Rg/ml: healthy controls (n=8), mean migration index= 101; coeliacs (n=12), mean migration index=1.08), nor by ovalbumin (100 Rg/ml: healthy controls (n=6), mean migration index=0 99; coeliacs (n=10), mean migration index= 1.06).
Puromycin at 15 ,ug/ml diminished migration inhibition by fraction B at 100 [xg/ml in three of four coeliac patients. The results of an indirect assay with fraction B are shown in Figure 4 . The migration of normal leucocytes is inhibited by culture supernatants of peripheral blood mononuclear cells from patients with coeliac disease incubated with fraction B at 1.2 ,tg/ml. In contrast, the results shown for the direct assay are with 80 times as much antigen.
Preincubation of normal leucocytes with sera from eight patients with coeliac disease did not sensitise these cells to the antigen, fraction B at 100 Ftg/ml (mean migration index of normal leucocytes exposed to coeliac sera=0-94; mean migration index of normal leucocytes exposed to normal sera= 1 04; not significantly different, p>O. 1).
A comparison of the results of the direct migration inhibition assay using gluten fraction B2 of Anand et al'4 and the new fraction B2 shows that these two fractions both inhibit the migration of leucocytes from coeliac patients to the same extent. Leucocytes from healthy subjects show very little inhibition with either fraction. In the disease controls there was no difference between the two fractions: for B2 at 10 [tg/ml, mean migration index=1-03 (n=10, SD= 0.09), while for new B2 at the same concentration, mean migration index=1-03 (n=10, SD=0 10).
For B2 at 100 pg/ml, mean migration index=1.04 (n=10, SD=0*09), while for new B2 at the same concentration, mean migration index=1.06 (n-10, SD=0 16). Figures 5 and 6 show the migration indices of leucocytes from normal individuals, patients with coeliac disease and disease controls exposed to 10 [ig/ml and 100 ,ug/ml of each of the peptide groups P1 to P4. There was significant migration inhibition of leucocytes from coeliac patients exposed to all four peptide groups. The migration indices in coeliac 1-6 P1 p<O-Ol). When leucocytes from healthy individuals were exposed in the indirect assay to the culture supernatants from mononuclear cells of five coeliac patients that had been incubated with antigens, their migration was inhibited (Fig. 7) . The antigens used to stimulate the coeliac cells were P1 and P3 at 1.2 ,ug!ml. patients with coeliac disease suggests that the lymphocytes from the patients retain their ability to produce migration inhibition factor(s) when stimulated with recall antigens.
FIll has been shown to be toxic to the coeliac intestinal epithelium by feeding experiments (reference 2 and, for Scout 66, P M Rawcliffe, unpublished work). FIll has also been reported to cause Gluten is a complex material which contains many proteins with closely similar physical characteristics and overall chemical composition. The available evidence suggests that they show a considerable degree of structural homology, both between and within individual gliadin molecules. The result of an incomplete peptic tryptic digest of gluten under the conditions of Frazer et al is yet more complex.
Fractions B and B2 inhibit migration of coeliac leucocytes while the preparation of Scout 66 FIII from which they derive does not. Ashkenazi and coworkers'7 found that migration inhibition was more marked when leucocytes from coeliac patients were incubated singly with either their B2 or their B3 subfraction than when they were incubated with a mixture of the two or with their FIII. They speculated that fractionation of FlIT into smaller peptides uncovers immunogenic sites which are again masked by remixing these fractions.
We have shown no effect of fractions B and B2 in healthy controls. Other workers"' have noted cell mediated immunity to our fraction B2 in non-coeliac patients with active small bowel diseases. Fraction B2 has now been separated into four peak groups, 2 each still containing many peptides, by reverse phase HPLC. All four peptide groups caused migration inhibition of leucocytes from patients with coeliac disease in the direct assay, at low concentrations. P4 was the most active. This effect was only seen with coeliac patients. The ability of culture supernatants to inhibit the migration of leucocytes from normal individuals suggests that lymphokine is produced by the stimulation of mononuclear cells from patients with coeliac disease by gluten derived peptides.
The indirect test was not performed with peptide groups P2 and P4 because of a lack of materials. Any 'active sequence' (or sequences) could be present in many of the peptides resulting from the partial digestion procedure used here. It need not therefore be surprising, at this level of separation, that all four peptide groups, each with a number of peptides, exhibit some degree of activity. They are the subject of further studies. 
